English | 繁體

Search in the results

UM

Browse/Search Results:  1-7 of 7 Help

Selected(0)Clear Items/Page:    Sort:
ENGINEERED CD9 ANTIBODIES AND THEIR USE Patent
专利类型: 发明专利 Invention, 专利号: US/63684204,
Authors:  ZHAO QI;  Fu Shengyu
Adobe PDF | Favorite |  | Submit date：2024/08/20
Antibody Recognition of Human Epidermal Growth Factor Receptor-2 (HER2) Juxtamembrane Domain Enhances Anti-Tumor Response of Chimeric Antigen Receptor (CAR)-T Cells Journal article
Zhou, Guangyu, Fu, Shengyu, Zhang, Yunsen, Li, Shuang, Guo, Ziang, Ouyang, Defang, Ying, Tianlei, Lu, Yinying, Zhao, Qi. Antibody Recognition of Human Epidermal Growth Factor Receptor-2 (HER2) Juxtamembrane Domain Enhances Anti-Tumor Response of Chimeric Antigen Receptor (CAR)-T Cells[J]. Antibodies, 2024, 13(2), 45.
Authors:  Zhou, Guangyu;  Fu, Shengyu;  Zhang, Yunsen;  Li, Shuang;  Guo, Ziang; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:3.0/4.7 | Submit date：2024/08/05
Car-t Cell  Her2  Monoclonal Antibody  Trastuzumab  
Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer Journal article
Cao, Bihui, Liu, Manting, Wang, Lu, Zhu, Kangshun, Cai, Mingyue, Chen, Xiaopei, Feng, Yunfei, Yang, Shuo, Fu, Shengyu, Zhi, Cheng, Ye, Xiaodie, Zhang, Jian, Zhang, Zhiru, Yang, Xin, Zhao, Ming, Wu, Qingde, Xu, Linfeng, Yang, Lili, Lian, Hui, Zhao, Qi, Zhang, Zhenfeng. Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer[J]. Nature Communications, 2022, 13(1), 6203.
Authors:  Cao, Bihui;  Liu, Manting;  Wang, Lu;  Zhu, Kangshun;  Cai, Mingyue; et al.
Favorite | TC[WOS]:48 TC[Scopus]:48  IF:14.7/16.1 | Submit date：2023/01/30
Growth  Antibody  Thermal Ablation  Receptor Tyrosine Kinases  
2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy Journal article
Peng, Yingjun, Fu, Shengyu, Zhao, Qi. 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy[J]. Journal of leukocyte biology, 2022, 112(4), 823-834.
Authors:  Peng, Yingjun;  Fu, Shengyu;  Zhao, Qi
Favorite | TC[WOS]:7 TC[Scopus]:7 | Submit date：2023/08/28
Quantitation and Identification of Therapeutic Anti-CD22 Monoclonal Antibodies in a Cell-Based ELISA Method Journal article
Fu, Shengyu, Zhao, Qi. Quantitation and Identification of Therapeutic Anti-CD22 Monoclonal Antibodies in a Cell-Based ELISA Method[J]. Antibodies, 2022, 11(3), 53.
Authors:  Fu, Shengyu;  Zhao, Qi
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:3.0/4.7 | Submit date：2022/08/27
Cd22  Elisa  Monoclonal Antibodies  
2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy Journal article
Yingjun Peng, Shengyu Fu. 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy[J]. Journal of Leukocyte Biology, 2022, 112(4), 823-834.
Authors:  Yingjun Peng;  Shengyu Fu
Favorite | TC[WOS]:7 TC[Scopus]:7  IF:3.6/5.2 | Submit date：2022/08/05
Cytokine  Il-15  Il-2  Immunotherapy  Protein Engineering  
Identification of novel FUS and TARDBP gene mutations in Chinese amyotrophic lateral sclerosis patients with HRM analysis Journal article
Wang, Feng, Fu, Shengyu, Lei, Jiafan, Wu, Hongchen, Shi, Shugui, Chen, Kangning, Hu, Jun, Xu, Xueqing. Identification of novel FUS and TARDBP gene mutations in Chinese amyotrophic lateral sclerosis patients with HRM analysis[J]. Aging, 2020, 12(22), 22859-22868.
Authors:  Wang, Feng;  Fu, Shengyu;  Lei, Jiafan;  Wu, Hongchen;  Shi, Shugui; et al.
Favorite | TC[Scopus]:7  IF:3.9/4.9 | Submit date：2021/12/06
Amyotrophic Lateral Sclerosis  Fus  Hrm Analysis  Tardbp